Physician profile
Roset D Samuel
NPI 1073590162
$1,696.26
in general payments reported to CMS, 2019-2025
17 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $13.28 · 2021: $549 · 2022: $64.01 · 2023: $29.10 · 2024: $190 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $352.19 | 2019-2021 | |
| Novo Nordisk INC | $307.99 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $250.58 | 2021-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.11 | 2019-2021 | |
| Globus Medical, INC. | $145.82 | 2025 | Senza |
| Phathom Pharmaceuticals, INC. | $127.17 | 2024 | Voquezna |
| Gilead Sciences, INC. | $98.84 | 2019 | |
| Abbott Laboratories | $43.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $40.74 | 2019-2022 | |
| Abbvie INC. | $34.64 | 2024 | |
| Janssen Pharmaceuticals, INC | $22.84 | 2021 | |
| Pfizer INC. | $16.68 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.62 | 2019 | |
| Becton, Dickinson and Company | $15.99 | 2023 | Bd Onclarity |
| Ultragenyx Pharmaceutical INC. | $14.34 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $14.20 | 2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $13.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roset Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.